Production (Stage)
Barinthus Biotherapeutics plc
BRNS
$0.8094
$0.155423.76%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -25.90% | -88.71% | 152.82% | -50.83% | 13.68% |
| Gross Profit | 25.90% | 88.71% | 1,853.75% | 27.13% | -19.61% |
| SG&A Expenses | 103.23% | -124.73% | 1,045.06% | -45.15% | -48.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -480.00% | -- | -- | -- | -- |
| Total Operating Expenses | 24.69% | -86.30% | 59.26% | -32.62% | -20.56% |
| Operating Income | -24.69% | 86.30% | 39.58% | 31.75% | 18.73% |
| Income Before Tax | -26.50% | -13.68% | 44.73% | 32.09% | 16.98% |
| Income Tax Expenses | 40.54% | 100.37% | 99.50% | 99.38% | 92.83% |
| Earnings from Continuing Operations | -26.66% | -19.09% | 42.39% | 28.88% | 14.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -67.74% | 1,800.00% | -60.53% | -45.45% | -27.91% |
| Net Income | -26.85% | -18.78% | 42.34% | 28.87% | 14.80% |
| EBIT | -24.69% | 86.30% | 39.58% | 31.75% | 18.73% |
| EBITDA | -21.86% | 89.17% | 41.43% | 33.04% | 20.17% |
| EPS Basic | -22.15% | -14.12% | 43.65% | 30.01% | 16.48% |
| Normalized Basic EPS | -22.39% | 90.09% | 44.33% | 33.19% | 17.52% |
| EPS Diluted | -22.50% | -13.62% | 43.24% | 30.05% | 16.67% |
| Normalized Diluted EPS | -22.39% | 90.09% | 44.33% | 33.19% | 17.52% |
| Average Basic Shares Outstanding | 3.85% | 4.07% | 2.30% | 1.65% | 2.00% |
| Average Diluted Shares Outstanding | 3.85% | 4.07% | 2.30% | 1.65% | 2.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |